University of Victoria - Genome British Columbia Proteomics Centre , University of Victoria , Victoria , British Columbia , Canada.
Department of Biochemistry and Microbiology , University of Victoria , Victoria , BC , Canada.
Expert Rev Proteomics. 2018 Sep;15(9):701-708. doi: 10.1080/14789450.2018.1516147. Epub 2018 Sep 17.
Biomarkers are commonly used to stratify cancer patients and guide targeted therapies, but most biomarkers are of a genomic nature. Discrepancies between the genome and proteome and the high rates of drug resistance indicate that proteomic analyses may provide additional critically important information. Here we present immuno-Matrix-Assisted Laser Desorption/Ionization (iMALDI), the combination of immuno-affinity enrichment of peptides followed by direct MALDI-mass spectrometry analysis. iMALDI is a highly sensitive, targeted protein-quantitation technique with the potential to measure clinically relevant signaling-pathway proteins using minimal sample amounts, thus improving upon existing methodologies. Areas covered: We provide a brief overview of the current state of biomarker analysis technologies for modern cancer treatment. We also show the advantages of iMALDI for translating potential new biomarkers into the clinic, factors to consider for iMALDI assay development, and the utility of iMALDI for the quantitation of cell-signaling proteins. Expert commentary: We see targeted mass spectrometry approaches such as iMALDI as an important part of improving patient responses to targeted therapies by providing highly sensitive, accurate, precise, and specific measurements of signaling-pathway proteins, both in tumor cells and in cells from the tumor microenvironment. iMALDI results can be integrated with other -omics data to aid in tumor-targeting therapies and immuno-oncology.
生物标志物通常用于对癌症患者进行分层并指导靶向治疗，但大多数生物标志物都具有基因组特性。基因组和蛋白质组之间的差异以及高耐药率表明，蛋白质组分析可能提供额外的极其重要的信息。在这里，我们介绍免疫基质辅助激光解吸/电离（iMALDI），这是一种将肽的免疫亲和富集与直接 MALDI-质谱分析相结合的方法。iMALDI 是一种高度敏感的靶向蛋白质定量技术，具有使用最小量样本测量临床相关信号通路蛋白的潜力，从而改进了现有的方法。涵盖领域：我们简要概述了用于现代癌症治疗的生物标志物分析技术的现状。我们还展示了 iMALDI 将潜在新生物标志物转化为临床应用的优势、用于 iMALDI 测定开发的考虑因素，以及 iMALDI 用于定量细胞信号蛋白的用途。专家评论：我们将 iMALDI 等靶向质谱方法视为通过对肿瘤细胞和肿瘤微环境中的细胞中的信号通路蛋白进行高度敏感、准确、精确和特异性测量，来提高患者对靶向治疗反应的重要手段。iMALDI 结果可以与其他组学数据相结合，以辅助肿瘤靶向治疗和免疫肿瘤学。
